Ann: September Quarterly Activity and Cashflow Report, page-49

Hi Footmax,

Thank you for explaining this in a rational manner, so that readers can understand this so called loan. It’s very helpful & that is what we need here, not chaos & fear mongering, just facts are good & certainly it’s ok for holders to question & discuss quarterlies, that’s normal.

Are you an accountant Footmax? Because I have a question. I’m not sure how it all works, but when MXC are conducting clinical trials in Australia & drug development, should they not be entitled to an R&D tax rebate from the ATO?

All other biotechs I’m invested in receive this & it’s generally in the $1-2 million dollar range, which I guess is to help companies recoup costs of running trials to better population health.

Wonder how things are going at Cannatech which began last night. PK is going to update us. . Cheers